A Phase 3, Randomized, Multicenter, Open-Label Study of IDRX-42 (GSK6042981) Versus Sunitinib in Participants With Metastatic and/or Unresectable Gastrointestinal Stromal Tumors (GIST) After Imatinib Therapy (StrateGIST 3)

The purpose of this study is to find out if a new drug, called IDRX-42 (also known as GSK6042981), is effective in treating adults with a type of cancer called Gastrointestinal Stromal Tumors (GIST) when compared to another drug named sunitinib. The study will see if IDRX-42 works well and is safe for participants whose GIST has spread or cannot be surgically removed, and who have already taken the drug imatinib.

开始日期2025-10-30

申办/合作机构

GSK Plc

CTIS2024-514930-19-00

/ Recruiting临床1/2期

A FIRST-IN-HUMAN (FIH) STUDY OF IDRX-42 IN PARTICIPANTS WITH METASTATIC AND/OR UNRESECTABLE GASTROINTESTINAL STROMAL TUMORS (GIST) - IDRX-42-001

开始日期2022-10-24

申办/合作机构

IDRx, Inc.

NCT05489237

/ Recruiting临床1期

A First-in-human (FIH) Study of IDRX-42 in Participants With Metastatic and/or Unresectable Gastrointestinal Stromal Tumors (GIST) [Study ID: StrateGIST 1]

This is the first clinical trial of IDRX-42. The study is designed to evaluate the safety, tolerability, PK, and preliminary antitumor activity of IDRX-42 in adult participants with advanced (metastatic and/or surgically unresectable) GIST.

开始日期2022-08-03

申办/合作机构-

100 项与 IDRX-42 相关的临床结果

登录后查看更多信息

100 项与 IDRX-42 相关的转化医学

登录后查看更多信息

100 项与 IDRX-42 相关的专利（医药）

登录后查看更多信息

项与 IDRX-42 相关的文献（医药）

2025-07-02·MOLECULAR CANCER THERAPEUTICS

M4205 (IDRX-42) Is a Highly Selective and Potent Inhibitor of Relevant Oncogenic Driver and Resistance Variants of KIT in Cancer

Article

作者: Grädler, Ulrich ; Dorsch, Dieter ; Ross, Edith ; Petersson, Carl ; Leuthner, Birgitta ; Sherbetjian, Eva ; Drechsler, Christine ; Linde, Nina ; Blum, Andreas ; Blaukat, Andree ; Esdar, Christina ; Schieferstein, Hanno

Abstract:

Primary activating mutations in KIT (exon 9/11) are key driver alterations in about 80% of gastrointestinal stromal tumors (GIST). Imatinib, a small-molecule tyrosine kinase inhibitor, is used successfully as first-line therapy for patients with unresectable metastatic or recurrent GIST, but secondary resistance mutations in the KIT kinase domains frequently occur. Currently approved later-line therapies target these mutations incompletely with limited clinical benefit. M4205, a kinome-selective KIT inhibitor, was designed to address this high unmet medical need by inhibiting all relevant KIT driver and resistance mutations. Compared with imatinib, M4205 shows stronger antitumor activity in preclinical GIST models driven by oncogenic KIT driver mutations. M4205 demonstrates clinically relevant efficacy in a range of preclinical GIST models expressing different secondary KIT resistance mutations. The kinase selectivity profile of M4205 is superior to the registered standard of care and investigational agents. M4205, now IDRX-42, is currently being investigated in a phase I first-in-human study in participants with GIST.

2023-08-01·Clinical cancer research : an official journal of the American Association for Cancer Research

Antitumor Efficacy of the Novel KIT Inhibitor IDRX-42 (Formerly M4205) in Patient- and Cell Line-Derived Xenograft Models of Gastrointestinal Stromal Tumor (GIST).

Article

作者: Schöffski, Patrick ; Verreet, Jasper ; Wozniak, Agnieszka ; Esdar, Christina ; Linde, Nina ; Sciot, Raf ; De Sutter, Luna ; Drechsler, Christine ; Vanleeuw, Ulla ; De Cock, Lore

PURPOSE:

The majority of gastrointestinal stromal tumors (GIST) are driven by constitutively activated KIT/PDGFRA kinases and are susceptible to treatment with tyrosine kinase inhibitors. During treatment, most of these tumors will develop secondary mutations in KIT or PDGFRA inducing drug resistance, so there is an unmet need for novel therapies. We tested the efficacy of IDRX-42, a novel selective KIT inhibitor with high activity toward the most relevant KIT mutations, in 4 GIST xenograft models.

EXPERIMENTAL DESIGN:

NMRI nu/nu mice were transplanted with patient-derived GIST xenograft models UZLX-GIST9 (KIT:p.P577del;W557LfsX5;D820G), UZLX-GIST2B (KIT:p.A502_Y503dup), UZLX-GIST25 (KIT:p.K642E), and the cell line-derived model GIST882 (KIT:p.K642E). Mice were treated daily with vehicle (control), imatinib (100 mg/kg), sunitinib (20 mg/kg), avapritinib (5 mg/kg), or IDRX-42 (10 mg/kg, 25 mg/kg). Efficacy was assessed by tumor volume evolution, histopathology, grading of histologic response, and IHC. The Kruskal-Wallis and Wilcoxon matched-pairs tests were used for statistical analysis, with P < 0.05 considered as significant.

RESULTS:

IDRX-42 (25 mg/kg) caused tumor volume shrinkage in UZLX-GIST25, GIST882, and UZLX-GIST2B, with a relative decrease to 45.6%, 57.3%, and 35.1% on the last day as compared with baseline, and tumor growth delay (160.9%) compared with control in UZLX-GIST9. Compared with controls, IDRX-42 (25 mg/kg) induced a significant decrease in mitosis. In UZLX-GIST25 and GIST882 grade 2-4 histologic response with myxoid degeneration was observed in all IDRX-42 (25 mg/kg)-treated tumors.

CONCLUSIONS:

IDRX-42 showed significant antitumor activity in patient- and cell line-derived GIST xenograft models. The novel kinase inhibitor induced volumetric responses, decreased mitotic activity, and had antiproliferative effects. In models with KIT exon 13 mutation IDRX-42 induced characteristic myxoid degeneration.

2023-02-23·Journal of medicinal chemistry1区 · 医学

Identification of M4205─A Highly Selective Inhibitor of KIT Mutations for Treatment of Unresectable Metastatic or Recurrent Gastrointestinal Stromal Tumors

1区 · 医学

Article

作者: Linde, Nina ; Blum, Andreas ; Glaser, Nina ; Brandstetter, Susanne ; Dorsch, Dieter ; Ruff, Aaron ; Petersson, Carl ; Busch, Michael ; Sherbetjian, Eva ; Buchstaller, Hans-Peter ; Esdar, Christina ; Grädler, Ulrich ; Schieferstein, Hanno

The treatment of gastrointestinal stromal tumors (GISTs) driven by activating mutations in the KIT gene is a prime example of targeted therapy for treatment of cancer. The approval of the tyrosine kinase inhibitor imatinib has significantly improved patient survival, but emerging resistance under treatment and relapse is observed. Several additional KIT inhibitors have been approved; still, there is a high unmet need for KIT inhibitors with high selectivity and broad coverage of all clinically relevant KIT mutants. An imidazopyridine hit featuring excellent kinase selectivity was identified in a high-throughput screen (HTS) and optimized to the clinical candidate M4205 (IDRX-42). This molecule has a superior profile compared to approved drugs, suggesting a best-in-class potential for recurrent and metastatic GISTs driven by KIT mutations.

项与 IDRX-42 相关的新闻（医药）

2025-07-25

·PipelineReview

Blenrep (belantamab mafodotin) combinations approved in EU for treatment of relapsed/refractory multiple myeloma

LONDON, UK I July 24, 2025 I GSK plc (LSE/NYSE: GSK) today announced the approval of Blenrep in the European Union (EU) for the treatment of adults with relapsed or refractory multiple myeloma in combination with bortezomib plus dexamethasone (BVd) in patients who have received at least one prior therapy, and in combination with pomalidomide plus dexamethasone (BPd) in patients who have received at least one prior therapy including lenalidomide. The approval is based on superior efficacy results demonstrated by Blenrep combinations in the pivotal DREAMM-7 and DREAMM-8 phase III trials in relapsed or refractory multiple myeloma. These include statistically significant and clinically meaningful progression-free survival (PFS) for Blenrep combinations versus triplet standard of care combinations in both trials and overall survival (OS) versus a daratumumab-based triplet in DREAMM-7. 2,3,4 The safety and tolerability profiles of the Blenrep combinations were broadly consistent with the known profiles of the individual agents. 2,3 Hesham Abdullah, Senior Vice President, Global Head Oncology, R&D, GSK, sai d: “Today’s approval of Blenrep combinations is a redefining moment for patients with relapsed or refractory multiple myeloma in the EU. Blenrep has the potential to extend remission and survival, with superior efficacy versus standards of care in our DREAMM clinical trial programme and the option to administer in both academic and community-based settings.” More than 50,000 cases of multiple myeloma are diagnosed in Europe each year, accounting for more than a quarter of global incidence. 5 Blenrep is the only anti-BCMA (B-cell maturation antigen) antibody-drug conjugate (ADC) approved in multiple myeloma, providing patients with a differentiated mechanism of action to potentially help slow disease progression and extend survival. 1 Blenrep combinations can be administered to a range of patient types across oncology treatment settings, enabling broad accessibility of an anti-BCMA therapy. María-Victoria Mateos, MD, PhD, Head of Myeloma and Clinical Trials Unit, Haematology Department and Professor of Medicine at the University of Salamanca, Spain, and DREAMM-7 principal investigator, said : “With the approval of Blenrep combinations in the EU, we now have additional tools in our efforts to keep patients in remission longer, maintain quality of life and extend survival. The robust efficacy supported by the DREAMM-7 and DREAMM-8 trials, together with manageable outpatient administration in academic and community settings, positions Blenrep combinations as a fundamentally differentiated treatment approach for multiple myeloma patients starting from first relapse.” Both DREAMM-7 and DREAMM-8 showed statistically significant and clinically meaningful PFS improvements for the Blenrep combinations compared to standard of care triplet combinations in the second line or later treatment of multiple myeloma. 2,3 In DREAMM-7, the Blenrep combination (n=243) nearly tripled median PFS versus the daratumumab-based comparator (n=251) (36.6 months versus 13.4 months, respectively (hazard ratio [HR]: 0.41 [95% confidence interval (CI): 0.31-0.53], p-value<0.00001). 2 DREAMM-7 also met the key secondary endpoint of OS, showing a statistically significant and clinically meaningful 42% reduction in the risk of death at a median follow-up of 39.4 months favouring the Blenrep combination versus the daratumumab-based comparator (HR: 0.58; 95% CI: 0.43-0.79; p=0.00023). The median OS was not reached in either arm of the study. The three-year OS rate was 74% in the Blenrep combination arm and 60% in the daratumumab combination arm. 4 In DREAMM-8, at a median follow-up of 21.8 months, the median PFS was not yet reached (95% CI: 20.6-not yet reached [NR]) with the Blenrep combination compared to 12.7 months in the bortezomib combination (95% CI: 9.1-18.5) at the time of primary analysis. 3 Blenrep combinations consistently benefited a broad range of patients, including those with poor prognostic features or outcomes, such as high-risk cytogenetics or those refractory to lenalidomide. Both trials also showed clinically meaningful improvements across all other secondary efficacy endpoints, including deeper and more durable responses versus the respective comparators. 2,3 DREAMM-7 and DREAMM-8 showed that eye-related side effects associated with Blenrep can be managed and reversed with appropriate dose modifications and follow-up. This allowed patients to maintain benefit and resulted in low rates of discontinuation due to eye-related side effects (≤9%) in both trials. 2,3 The most commonly reported non-ocular adverse events (>30% of participants) in the Blenrep combination arm were thrombocytopenia (87%) and diarrhoea (32%) in DREAMM-7, and neutropenia (63%), thrombocytopenia (55%) and COVID-19 (37%) in DREAMM-8. 2,3 Blenrep combinations are also approved in relapsed or refractory multiple myeloma in the UK 6 and Japan 7 as well as other markets, including Canada and Switzerland (based on the results of DREAMM-8). Applications are currently under review in all major markets globally, including the US 8 and China 9 (based on the results of DREAMM-7, with Breakthrough Therapy Designation for the combination and priority review for the application). About multiple myeloma Multiple myeloma is the third most common blood cancer globally and is generally considered treatable but not curable. 10,11 There are approximately more than 180,000 new cases of multiple myeloma diagnosed globally each year. 5 Research into new therapies is needed as multiple myeloma commonly becomes refractory to available treatments. 1 Many patients with multiple myeloma are treated in a community cancer setting, leaving an urgent need for new, effective therapies with manageable side effects that can be administered outside of an academic centre. 12,13 About Blenrep Blenrep is an ADC comprising a humanised BCMA monoclonal antibody conjugated to the cytotoxic agent auristatin F via a non-cleavable linker. The drug linker technology is licensed from Seagen Inc.; the monoclonal antibody is produced using POTELLIGENT Technology licensed from BioWa Inc., a member of the Kyowa Kirin Group. Indication In the EU, Blenrep is indicated in adults for the treatment of relapsed or refractory multiple myeloma: IMPORTANT SAFETY INFORMATION FOR BLENREP Refer to the Blenrep EMA Reference Information 14 which will soon be available for a full list of adverse events and the complete important safety information in the EU. About DREAMM-7 DREAMM-7 is a multicentre, open-label, randomised phase III clinical trial evaluating the efficacy and safety of belantamab mafodotin combined with bortezomib plus dexamethasone (BVd) compared to daratumumab combined with bortezomib plus dexamethasone (DVd) in patients with relapsed or refractory multiple myeloma who previously were treated with at least one prior line of multiple myeloma therapy, with documented disease progression during or after their most recent therapy. The trial enrolled 494 participants who were randomised 1:1 to receive either BVd or DVd. Belantamab mafodotin was administered at a dose of 2.5mg/kg intravenously every three weeks in combination for the first eight cycles and then continued as a single agent. The primary endpoint was PFS as per an independent review committee, with secondary endpoints including OS, duration of response (DOR), and minimal residual disease (MRD) negativity rate as assessed by next-generation sequencing. Other secondary endpoints include overall response rate (ORR), safety, and patient reported and quality of life outcomes. PFS results were presented at the American Society of Clinical Oncology (ASCO) Plenary Series in February 2024 and published in the New England Journal of Medicine . OS results were presented at the American Society of Hematology (ASH) Annual Meeting in December 2024. 2,4 About DREAMM-8 DREAMM-8 is a multicentre, open-label, randomised phase III clinical trial evaluating the efficacy and safety of belantamab mafodotin in combination with pomalidomide plus dexamethasone (BPd) compared to bortezomib and pomalidomide plus dexamethasone (PVd) in patients with relapsed or refractory multiple myeloma previously treated with at least one prior line of multiple myeloma therapy, including a lenalidomide-containing regimen, and who have documented disease progression during or after their most recent therapy. The trial included 302 participants who were randomised 1:1 to receive either BPd or PVd. Compared to the patient population studied in the DREAMM-7 trial, patients in DREAMM-8 were more heavily pre-treated in that all had prior exposure to lenalidomide, 78% were refractory to lenalidomide, 25% had prior daratumumab exposure and of those most were daratumumab refractory. Belantamab mafodotin was administered at a dose of 2.5mg/kg intravenously for the first cycle and then 1.9mg/kg intravenously every four weeks. The primary endpoint was PFS as per an independent review committee, with key secondary endpoints including OS and MRD negativity rate as assessed by next-generation sequencing. Other secondary endpoints include ORR, DOR, safety, and patient reported and quality of life outcomes. Results were first presented at the 2024 ASCO Annual Meeting and published in the New England Journal of Medicine . 3 Updated PFS results were presented at the European Hematology Association (EHA) Congress in June 2025. 15 GSK in oncology Our ambition in oncology is to help increase overall quality of life, maximise survival and change the course of disease, expanding from our current focus on blood and women’s cancers into lung and gastrointestinal cancers, as well as other solid tumours. This includes accelerating priority programmes such as antibody-drug conjugates targeting B7-H3 and B7-H4, and IDRX-42, a highly selective KIT tyrosine kinase inhibitor. About GSK GSK is a global biopharma company with a purpose to unite science, technology, and talent to get ahead of disease together. Find out more at gsk.com. References SOURCE: GlaxoSmithKline

临床结果临床3期上市批准ASCO会议突破性疗法

2025-05-10

·药事纵横

总额超266亿美元！2025Q1药企大手笔并购TOP5

12 大平行论坛构筑知识矩阵，300+全球意见领袖智慧碰撞，5000+专业观众精准资源对接，10 场系列同期会议活动，扫码抢占席位声明：因水平有限，错误不可避免，或有些信息非最及时，欢迎留言指出。本文仅作医疗健康相关药物介绍，非治疗方案推荐（若涉及）;本文不构成任何投资建议。2025年Q1，全球医药行业迎来了一波交易热潮。据不完全统计，并购（M&A）交易有8笔，总金额超过266亿美元，涉及肿瘤、代谢疾病、精神健康等核心治疗领域，肿瘤领域仍是并购核心，共4笔交易，占比50%。其中，并购金额TOP5整理如下：1.强生＆Intra-Cellular Therapies1月13日，强生宣布将以146亿美元的总估值收购生物制药公司Intra-Cellular Therapies，创下目前年内最高交易额，并已于4月完成收购。强生豪掷100多亿美元瞄准的是Intra-Cellular旗下一款药物——Caplyta（lumateperone 卢美哌隆），该药在上市后销量飞涨。CAPLYTA®是一种每日一次的口服疗法，已获批准用于治疗成人的精神分裂症，同时也是首个且唯一获得美国食品药品监督管理局（FDA）批准的用来作为单药治疗和与锂或丙戊酸钠联合治疗双相I型或II型障碍（双相抑郁）相关抑郁发作的药物。2025年2月，细胞内治疗公司宣布，FDA已接受其CAPLYTA®作为成人重度抑郁症（MDD）辅助治疗的补充新药申请。此次收购还包括ITI-1284，这是一种有前景的第二阶段化合物，正在研究其对广泛性焦虑症（GAD）和阿尔茨海默病相关的精神疾病和焦虑的疗效，以及进一步补充强生当前关注领域的临床阶段管线。该交易预计将推动强生2025年的销售增长约0.8%，新增销售额约为7亿美元。2.贝恩资本＆田边三菱制药2月7日，美国私募股权巨头贝恩资本（Bain Capital ）以5100亿日元（34亿美元）的价格收购了田边三菱制药公司，称其对日本制药行业监管变化的前景感到鼓舞。去年12月，黑石资本和贝恩资本竞标田边三菱制药。卖方三菱化学（Mitsubishi Chemical）表示之所以出售，是因为它无法提供加强田边三菱研发能力所需的大规模投资。出售所得将用于投资其核心化学品业务，并帮助其减少债务和提高股东回报。对于贝恩资本此次收购三菱田边，是其亚洲医疗战略的关键拼图：补齐慢性病赛道：慢性病药物市场占全球药品份额超50%，且不受经济周期影响，与贝恩现有肿瘤、器械业务形成互补；押注日本创新药“第二春”：日本政府近年大力推动“数字医疗”“细胞治疗”，三菱田边的研发底子+贝恩的资本助力，可能催生下一个重磅炸弹；剑指中国市场：三菱田边在中国已有糖尿病药物布局，贝恩或借其渠道加速引入海外创新药，抢占中国医保“腾笼换鸟”红利。3.诺华＆Anthos Therapeutics2月11日，诺华宣布以近31亿美元的价格收购Anthos Therapeutics，公司拥有abelacimab，一种正在开发的用于预防心房颤动患者中风和全身栓塞的晚期药物。该交易预计将于2025年上半年完成，同时受惯例成交条件的约束。2019年，黑石集团（Blackstone）旗下的生命科学基金Blackstone Life Sciences与诺华共同创立Anthos Therapeutics，其仅有一款核心管线abelacimab，abelacimab由诺华授权，Anthos负责开发、制造和商业化，诺华则获得Anthos的部分股权，这一模式与今天国内大火的"NewCo"类似。Abelacimab是一款靶向凝血因子FXI/FXIa的单抗，在开发早期，诺华由于风险控制等因素，选择与黑石集团合作，成立Anthos Therapeutics，并将Abelacimab剥离到该公司。由黑石主导早期开发。目前，Anthos已开始进行Abelacimab的III期试验，入组患者为不适合口服抗凝治疗的高危房颤患者，数据可能会在2026年公布。也许是看到Abelacimab的成药潜力，诺华决定收购Anthos，拿回abelacimab的权益。黑石得以成功退出，并收获丰厚回报，可谓双赢。4.礼来＆Scorpion Therapeutics1月11日，礼来拟按25亿美元的价格收购Scorpion Therapeutics，其中包括10亿美元预付款及总额高达15亿美元的潜在里程碑付款，而Scorpion最核心的管线为处于临床二期的PI3Kα抑制剂STX-478。STX-478是一种每日口服一次的突变体选择性PI3Kα抑制剂，目前正在进行1/2期临床试验，用于治疗乳腺癌和其他晚期实体瘤。STX-478旨在改善携带PI3Kα突变患者的治疗效果，PI3Kα突变是癌症最常见的驱动因素之一。在临床前模型中，STX-478针对多种PI3Kα突变体表现出强大的活性，同时在正常组织中避免了对野生型PI3Kα的抑制，从而克服现有PI3Kα通路药物的主要局限性。这种方法可能通过更深入的通路抑制提供更好的疾病控制，同时改善患者的耐受性。5.GSK＆IDRx1月13日，葛兰素史克与IDRx达成收购协议，获得后者开发的KIT抑制剂IDRX-42。根据协议，葛兰素史克支付10亿美元预付款，1.5亿美元监管里程碑金额，以及德国默克负责区域的里程碑金额和一定比例的销售分成。本次收购包括IDRx的主打候选药物IDRX-42，这是一种具有高度选择性的KIT酪氨酸激酶抑制剂，正在开发用于胃肠道间质瘤（GIST）患者的一线和二线治疗。IDRX-42已展示出对所有关键的原发性和继发性KIT突变体的活性，其设计旨在改善GIST患者的治疗效果。凭借其广泛的突变覆盖能力，以及可能提高耐受性的高度选择性，IDRX-42具有成为“best-in-class”药物的潜力。参考资料：www.biospace.com-END-2025CMC-CHINA药博会 • 展位火热预定中！

并购细胞疗法免疫疗法

2025-02-24

·Pharmaindustrial

GSK Completes Acquisition of IDRx

GSK has completed the acquisition of IDRx, a Boston-based, clinical-stage biopharmaceutical company dedicated to developing precision therapeutics for the treatment of gastrointestinal stromal tumours (GIST). As announced previously, the acquisition includes lead molecule IDRX-42, an investigational, highly selective tyrosine kinase inhibitor (TKI) that is designed to improve outcomes for patients with GIST. IDRX-42 has demonstrated activity against all clinically relevant primary and secondary KIT mutations, a key medical need in current GIST treatment. GIST typically presents in the gastrointestinal (GI) tract with 80 percent of cases driven by mutations in the KIT gene that lead to the growth, proliferation, and survival of tumour cells (primary or activating mutations).2 90 percent of patients treated in the first line develop new KIT mutations (secondary or resistance mutations) that typically lead to relapse with limited therapeutic options. Hesham Abdullah, Senior Vice President, Global Head Oncology R&D, GSK, said, “This acquisition adds to GSK’s growing pipeline of targeted therapeutics for cancers originating in the gastrointestinal tract. We plan to advance IDRX-42 for second line treatment of gastrointestinal stromal tumours, where there are no approved treatments to effectively address all resistance mutations, and accelerate development in an earlier setting.” The total cash consideration for this acquisition amounts to up to USD 1.15 billion. This includes an upfront payment of USD 1 billion, with the possibility of an additional USD 150 million milestone payment contingent upon success-based regulatory approval. GSK will also be responsible for success-based milestone payments as well as tiered royalties for IDRX-42 owed to Merck KGaA, Darmstadt, Germany.

并购临床研究

100 项与 IDRX-42 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
不可切除的胃肠道间质瘤	临床3期	-	GSK Plc	2025-10-30
胃肠道间质瘤	临床1期	美国	IDRx, Inc.	2022-08-03
胃肠道间质瘤	临床1期	美国	Aptuit (Verona) Srl	2022-08-03
胃肠道间质瘤	临床1期	比利时	Aptuit (Verona) Srl	2022-08-03
胃肠道间质瘤	临床1期	比利时	IDRx, Inc.	2022-08-03
胃肠道间质瘤	临床1期	法国	IDRx, Inc.	2022-08-03
胃肠道间质瘤	临床1期	法国	Aptuit (Verona) Srl	2022-08-03
胃肠道间质瘤	临床1期	德国	IDRx, Inc.	2022-08-03
胃肠道间质瘤	临床1期	德国	Aptuit (Verona) Srl	2022-08-03
胃肠道间质瘤	临床1期	意大利	Aptuit (Verona) Srl	2022-08-03

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT05489237 (StrateGIST1 \| StrateGIST 1, BusinessWire) 人工标引	临床1期	胃肠道间质瘤 KIT Mutation	89	IDRX-42	網窪齋鹹膚築衊鏇醖簾(鏇願顧製製構獵繭膚願) = 鬱襯網遞願顧襯積衊餘壓廠顧繭壓顧範鏇遞襯 (糧簾襯窪壓鑰廠顧壓淵 ) 更多	积极	2024-11-14
NCT05489237 (StrateGIST1 \| StrateGIST 1, BusinessWire) 人工标引	临床1期	胃肠道间质瘤 KIT Mutation	89	IDRX-42 (second-line)	網窪齋鹹膚築衊鏇醖簾(鏇願顧製製構獵繭膚願) = 願積網獵衊壓膚夢築憲壓廠顧繭壓顧範鏇遞襯 (糧簾襯窪壓鑰廠顧壓淵 ) 更多	积极	2024-11-14
NCT05489237 (StrateGIST 1, Biospace) 人工标引	临床1期	胃肠道间质瘤 KIT Mutation	73	IDRX-42	獵膚淵觸繭範壓餘襯齋(顧廠觸製蓋鹹襯鹽淵網) = 衊蓋壓簾蓋廠鏇衊壓積鹹艱鬱構衊膚淵獵憲網 (餘積鬱艱夢獵鏇築醖淵 ) 更多	积极	2024-07-03
NCT05489237 (StrateGIST 1, ASCO2024)	临床1期	转移性胃肠道间质瘤	42	IDRX-42 120 mg QD	淵網憲鬱積願艱鹹觸壓(齋膚遞艱製簾廠醖鑰鹽) = 鏇範淵願夢範願鑰窪餘鏇窪繭範廠窪顧鏇夢醖 (壓構齋願遞構製鬱積襯 ) 更多	积极	2024-05-24
NCT05489237 (StrateGIST 1, ASCO2024)	临床1期	转移性胃肠道间质瘤	42	IDRX-42 240 mg QD	淵網憲鬱積願艱鹹觸壓(齋膚遞艱製簾廠醖鑰鹽) = 膚襯醖憲鏇壓繭餘齋蓋鏇窪繭範廠窪顧鏇夢醖 (壓構齋願遞構製鬱積襯 ) 更多	积极	2024-05-24
NCT05489237 (StrateGIST1, Biospace) 人工标引	临床1期	胃肠道间质瘤 KIT Mutation	33	IDRX-42	簾範鏇糧齋構艱簾鏇獵(齋廠膚願糧壓製網遞選) = NR 鹹齋齋製鏇夢獵憲獵選 (觸窪糧網製繭淵窪淵製 ) 更多	积极	2023-11-02